Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Long-Term Deferred Tax: 2015-2018

  • Lifecore Biomedical's Long-Term Deferred Tax fell 28.87% to $17.5 million in Q2 2018 from the same period last year, while for May 2018 it was $17.5 million, marking a year-over-year decrease of 28.87%. This contributed to the annual value of $17.5 million for FY2018, which is 28.87% down from last year.
  • Per Lifecore Biomedical's latest filing, its Long-Term Deferred Tax stood at $17.5 million for Q2 2018, which was down 28.87% from $24.6 million recorded in Q2 2017.
  • In the past 5 years, Lifecore Biomedical's Long-Term Deferred Tax ranged from a high of $32.2 million in Q2 2015 and a low of $17.5 million during Q2 2018.
  • Its 3-year average for Long-Term Deferred Tax is $21.5 million, with a median of $22.4 million in 2016.
  • Per our database at Business Quant, Lifecore Biomedical's Long-Term Deferred Tax tumbled by 30.37% in 2016 and then rose by 9.53% in 2017.
  • Quarterly analysis of 4 years shows Lifecore Biomedical's Long-Term Deferred Tax stood at $32.2 million in 2015, then crashed by 30.37% to $22.4 million in 2016, then grew by 9.53% to $24.6 million in 2017, then decreased by 28.87% to $17.5 million in 2018.
  • Its last three reported values are $17.5 million in Q2 2018, $24.6 million for Q2 2017, and $22.4 million during Q2 2016.